Member Info for TrollHunter2

Smart move Football. The usual expected and predictable end of year sell off is nearly over and we're heading into the holiday period. January is buying season when investors tack up their positions for thé year ahead. C.Diff is derisked with solid P2 results and the company fully funded and pushing the blockbuster DMD programme forward at full pace now, Summit will be a prime target for investors expecting transformational news in 2017. GLA

Thanks gmcc ans Chris. With governments setting up huge funds to offer bio's with antibiotics, and c diff being on their list of high priority, Summit may now plan to take RDZ to market themselves or at least do P3 before partnering. Since the huge deal with srpt they certainly have no operating cash concerns, so long term this may be seen as the most lucrative route for shareholders. As many experts have said, the c.diff problem will only worsen until they have a better solution and RDZ has been discussed by UK's leading expert as the current best hope. GLA.

And there's your answer Osaka. GL, DYOR.....read back a few months.

Good news, the first PhaseOut DMD trial site is up and running in the US. As I understand it, it takes time to negotiate and setup each site so this is a significant step forward. Good luck to all involved, fingers and everything crossed for positive results and outcomes. GLA

No problem. Found time to listen myself. Nothing new for us but deep into Ridi P3 planning and confident should be starting P3 next year with a partner. All progressing to plan but at drug development speed. GLA

Hi GMCC, You wish is granted courtesy of the other side .... happy listening... you need to download the file to listen to it. htTps://recordings.join.me/ezyFo7graka6cXR8nmjkoQ RDZ from 171. John Tinsley

Thanks everyone for thé PM's and I completely agree and that is certainly the best way forward. GLA.

Yep, tiny amount of shares though, I have more than that in my SIPP :-) I see that employees could be taking the opportunity for easy cash and buying at their exercise price of 60p and cashing in with the rising share price now. Or maybe now they have a $522 million deal signed on the table they are more confident in the corporate side and to buy in and hold knowing they can take care of the science to deliver that full $522million. Either way, they very much deserve it and good luck to them. GLA

Yes, I agree straight. You will also notice the BoD have not been able to buy in the recent lows as they know they are banging the deals together. Only takes a little insight and research.... In the bag clearly. DYOR though, don't take my word for it. Watch out for the derampers, they'll cost you at their pleasure. Signing out now until deal announced. GLA

Agreed Xtra, C.Diff deal in the bag, it's just a matter of timing and how much. GLA

I been looking back through the share option awards, from 2012 : http://g923gvc6go14zuzz1vaotb19.wpengine.netdna-cdn.com/wp-content/uploads/2014/10/12_RNS_10-Grant-of-Options-May-2012-FINAL.pdf I think they missed the 2015 target, but 2017 is all to play for. So they have to double the share price to £4 by March 2017 and keep it there for 60 days. How are they going to do that.... C.Diff deal maybe ? Interesting that the exercise price would be 60p now...well below market price, so a massive incentive to pull it out of the bag... that's if it really is in the bag, as we expect :-) With the 20-1 consolidation 4,150,000 becomes 207,500 share if sp = £4 There are also other trances at £6, £8 and £10 but I guess £4 is ambitious enough at this point! The PoC on Ezutromid should certainly do it but we do not expect that until Q2/3 2017. It's certainly going to be an interesting few months ahead. GLA

Maybe due to Sarepta investor interest after the DMD conference calls. Either way, good to see the price holding up now.. seems to have found a bottom and new investors now buying in. GLA Long way to go yet chaps but nice to see things moving :-)

Yes, Ollieh, laughable. But employees taking up options is a good sign all is going well. Our SP drop in the past couple of days is in line with Sarepta who received some bad news. I guess the market have us even closer linked now we are partnered, but do not understand that a knock back in Exondys51 does not impact EZD. As you say, so few shares and so much to gain. Do your own research. GLA

Seems employees are confident and happy with their work. All good signs. Roll on EZD PoC. Roll on RDZ deal Roll on SP = £20 :-) I like the answer to N-1 Q's below which shows a bit more detail of how much and when Summit receive piles of cash from the Sarepta deal and I note they get $82millon in total before registration, and then $150million on approval....should definitely keep them going a while :-) "Q: When are the next milestones? A: The first milestone following the US$40m upfront is US$22m upon the first dosing of the last patient in Summit’s ongoing Phase II clinical trial (referred to as PhaseOut DMD) of ezutromid. The US$22m milestone is payable on or after 1 April 2017. In relation to ezutromid, Summit is eligible to receive up to a further US$20m in specified development milestones, up to US$150m in specified regulatory milestones and up to US$330m in sales milestones. Details of what triggers the milestone and its quantum are undisclosed.Summit is also eligible to escalating royalties ranging from low to high teens percentage of net sales in the licensed territories as well as additional milestones on its next-generation utrophin modulators. If Sarepta elects to exercise its option for Latin American rights, Summit would be entitled to additional fees, milestones and royalties."

Yep, the deal is in the bag chaps. Load up and wait. GLA

"The deal with Sarepta provides Summit with an upfront milestone of US$40m, strengthening Summit’s balance sheet and enabling it to continue partnership discussions from a strong position." GLA

Not sure anything brewing we don't know. We were told enough yesterday to justify a much higher SP. People were paying upto $19.75 yesterday.... so quite a bit to go to get back to initial reaction after the traders have taken their slice of the action. My guess is that Richard Griffiths may have taken the opportunity to sell more of his holding into the rise which supressed to gains on NASDAQ yesterday. Each to his own and good luck to him...not that he needs any more luck :-)

Agreed Ego. Sarepta have only bought the rights to Europe and Russian states. Summit will get 13-20% of those sales too without having to get involved in marketing or costs and problems of regulatory battles. Summit retain full market rights for US/Canada and Japan, Australia etc.... CEO on C.Diff "will be a path to market and value for shareholders", announcement on that for another day... today is about Sarepta deal and DMD. Well done on your top-up too. Looks like you did make a quick and correct decision. Looking forward to your inputs and insights as our little money fountain develops :-)

Best ignore the troll, I am from now on. It's great to see he's paying attention to how much he's missing out on here with all his money trapped in PLE and no hope of recovery. At least he keeps reminding us how bad it is for those on the side-lines, watching us leap forward with each company statement. Oh yes, and don't tell him anything, let him do his own research. If he thinks this company cannot turn into a pharma and produce it's own marketable drugs in the states then let him loose out again. Leave him out. I'm happy watching until the next transformational RNS now... this little biotech is now fully funded to become an emerging pharmaceutical and has now proven it can make deals with the bigger players... roll on next one. GLA

Well done all LTH's and the board for putting this deal together. My SIPP looks great now, more than double investment. Shame I have wait 10 years until I'm 55 to touch it, but then Summit will most likely 10 bag a couple of times from here over the coming couple of years so I happy to keep holding and watch this fantastic money fountain evolve. Good work all researchers and contributors, GMCC, AMM, F-M and Chris st. al.